Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome

Exclusion Criteria

• •Deletion of the 5q chromosome \[del(5q) MDS\]
• •Prior allogenic bone marrow transplant for MDS
• •Known sensitivity to ezatiostat (injection or oral tablets)
• •Prior treatment with hypomethylating agent (HMA) (e.g., azacitadine, decitabine)
• •History of MDS IPSS risk score of greater than 1.0
• •Pregnant or lactating women
• •Any severe concurrent disease, infection or comorbidity that, in the judgement of the investigator, would make the patient inappropriate for study entry
• •Oral steroids greater than 10 mg per day. Exceptions: those prescribed for other conditions (such as new adrenal failure, asthma, arthritis) or brief sterioid use (such as tapered dosing for an acute non-MDS condition)
• •History of hepatitis B or C, or HIV